Breakthrough trial aims to prevent arthritis in psoriasis patients

NCT ID NCT05004727

Recruiting now Prevention Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug guselkumab can prevent psoriatic arthritis in people with psoriasis who are at high risk. 176 adults with psoriasis and early signs of joint inflammation will receive either guselkumab or standard care. The goal is to see if the drug can stop arthritis from developing over two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Memorial University
RECRUITING

St. John's, Newfoundland and Labrador, A1C 5B8, Canada
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
University of Rochester Medical Center (URMC)
RECRUITING

Rochester, New York, 14623, United States
Women's College Research Institute, University of Toronto
RECRUITING

Toronto, Ontario, M5S 1B2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.